Focal Radiation and CD47 Blockade Synergy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in effectively targeting and eliminating cancer cells, particularly those expressing high levels of CD47, which evade immune surveillance and resist phagocytosis, leading to tumor growth and metastasis.
Innovation Solution
Combining focally delivered ionizing radiation therapy with an agent that inhibits the binding between CD47 and SIRPα, such as magrolimab, to induce synergistic reduction in tumor growth, promoting phagocytosis and immune response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD47-blocking monoclonal antibodies are used to inhibit tumor growth, then cancer cell elimination is improved, but radiation sensitivity and treatment efficacy are worsened due to CD47's radioprotective effects
Solution Approach 1:
The patent applies preliminary action by administering CD47-blocking monoclonal antibodies before radiation therapy to prevent the radioprotective effect of CD47. By blocking CD47 expression on cancer cells prior to radiation exposure, the treatment eliminates the protective mechanism that would otherwise reduce radiation-induced cell death, thereby enhancing overall treatment efficacy.
Solution Approach 2:
The patent merges two therapeutic approaches: CD47 blockade and radiation therapy. By combining anti-CD47 monoclonal antibodies with radiation treatment, the invention creates a synergistic effect where the antibody blocks the radioprotective pathway while radiation delivers cytotoxic damage, resulting in enhanced cancer cell elimination compared to either treatment alone.
2Reliability
If high doses of radiation are used to kill cancer cells, then tumor cell death is improved, but damage to normal cells and toxicity are worsened
Solution Approach 1:
The patent applies local quality by using focally delivered radiation therapy that concentrates the radiation dose specifically at the tumor site while minimizing exposure to surrounding normal tissues. This localized approach allows for high radiation doses to be delivered to cancer cells without proportionally increasing damage to normal cells, thereby improving the therapeutic ratio.
3Reliability
If CD47 expression is increased on cancer cells to evade immune surveillance, then immune evasion is improved, but phagocytosis and immune recognition are worsened
Solution Approach 1:
The patent applies the taking out principle by specifically targeting and blocking the CD47 molecule on cancer cells using monoclonal antibodies. By extracting or neutralizing the CD47 signal that mediates immune evasion, the treatment removes the protective mechanism that prevents phagocytosis, thereby enabling immune cells to recognize and engulf cancer cells effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy achieves a synergistic effect of reducing tumor burden by enhancing cancer cell death and immune response, leading to significant tumor regression and metastasis inhibition, even in non-irradiated tumors.
Implementation Method 1
focally-delivered ionizing radiation therapy
Implementation Method 2
enables the phagocytosis and elimination of cancer cells
Data Source
AI summary
Provided are methods of treating, mitigating, reducing, preventing or delaying the growth, proliferation, recurrence or metastasis of a solid cancer in a mammalian subject in need thereof comprising co-administering to the subject an effective amount of radiation therapy (RT) focally-delivered to the solid cancer; and an agent that inhibits binding between CD47 and SIRPα.